Related Organizations
- Pages
- 38
- Published in
- United States of America
Biomarker Analysis of the Aspen Study Comparing Zanubrutinib to Ibrutinib in Patients With Waldenström Macroglobulinemia
2024
<Macro 'access_denied_modal'>
<Macro 'unauthorized_modal'>
Add to list
Citation
IWMF, 2024. Biomarker Analysis of the Aspen Study Comparing Zanubrutinib to Ibrutinib in Patients With Waldenström Macroglobulinemia, IWMF: International Waldenstrom's Macroglobulinemia Foundation.
United States of America.
Retrieved from https://coilink.org/20.500.12592/5xdv24q on 15 Nov 2024. COI: 20.500.12592/5xdv24q.
Full-page Screenshot
